Biotech的“二次创业”:NewCo模式能否跑出下一个“百济神州”?

21世纪经济报道
28 May

创新药:爆款,突围,与自证编者按:创新药行业正迎来政策扶持、产业升级与业绩回暖的“三重共振”,资本市场估值逻辑加速重构,“熊市思维”下的传统评估方式已难适用。21世纪经济报道将持续聚焦行业热点——从BD交易模式到全球化竞争策略,从高估值背后的风险到政策波动的应对,推出系列报道专题《创新药:爆款,突围,与自证》,深入解读创新药企如何在变革中穿越周期,重塑价值坐标,定义行业新未来,此篇为第四篇。21...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10